Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 5, 2007

ART and Canada’s Institute for Biological Sciences Ally to Advance Diagnostics

  • ART Advanced Research Technologies is collaborating with the National Research Council of Canada's Institute for Biological Sciences (NRC-IBS) to develop client-oriented diagnostic applications.

    ART will implement its time domain (TD) technology for R&D activities under this partnership. The collaborators expect to expand the diagnostic applications of this platform and related equipment for use in various disease models.

    “The NRC-IBS is very pleased to collaborate with ART for the development of better diagnostics using molecular imaging, which can help identify and characterize brain-specific targets, and develop improved therapies for neurodegenerative diseases affecting the aging population,” says Abedelnasser Abulrob, Research Officer at the NRC-IBS. “Optical imaging-based approaches also promise to accelerate drug evaluation.”

    Abulrob's team has been using ART's in vivo optical imager, Optix® MX2, for new applications of optical imaging and fluorescence lifetime in addition to the evaluation of drugs in stroke, Alzheimer's disease and brain cancer. ART’s second TD-based tool is called SoftScan® and for the detecttion and diagnosis breast cancer.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »